Showing 4201-4210 of 5911 results for "".
- Kaustabh Ghosh, PhD, Recognized With Catalyst Award for Innovative AMD Researchhttps://modernod.com/news/dr-kaustabh-ghosh-recognized-with-catalyst-award-for-innovative-amd-research/2481657/Doheny Eye Institute announced that Kaustabh Ghosh, PhD, was recently recognized by non-profits Research to Prevent Blindness (RPD) and the International Retinal Research Foundation (IRRF) with the Catalyst Award for innovative approaches for age-related macular degeneration (AMD). 
- AOS Launches Remote Visual Acuity System Platformhttps://modernod.com/news/aos-launches-remote-visual-acuity-system-platform/2481652/AOS (Advanced Ophthalmic Systems) announced the launch of a new remote visual acuity software platform. The AOS VA software is a synchronous test that requires internet connection and can be used on multiple device types. Using a combination of semi-automated test algorithms a
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy/2481648/EyePoint Pharmaceuticals announced it has completed enrollment in the phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential 9-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). “We are delighted to report the completion of enrollment in
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- Gamesquare Partners with Vivior to Help Gamers Build Healthy Screen Habitshttps://modernod.com/news/gamesquare-partners-with-vivior-to-help-gamers-build-healthy-screen-habits/2481646/GameSquare Holdings announced a multi-year, multi-million dollar partnership with Swiss vision care startup Vivior with the aim of promoting healthy digital habits, according to a company news release. Through content creation, product development, and competition, GameSquare and Vivior
- Optos Announces New Ultra-Widefield Color Image Modality, Providing Additional Retinal Visualizationhttps://modernod.com/news/optos-announces-new-ultra-widefield-color-image-modality-providing-additional-retinal-visualization/2481645/Optos announced it is expanding the optomap ultra-widefield (UWF) retinal imaging modalities in the California FA device to further assist eye care professionals in disease management and treatment planning. In addition to optomap color rg (red/green), sensory red-free, c
- Annexon Announces Topline Data from Phase 2 Trial of ANX007 in Geographic Atrophyhttps://modernod.com/news/annexon-announces-topline-data-from-phase-2-trial-of-anx007-in-geographic-atrophy/2481637/Annexon announced topline results from its ARCHER phase 2 trial of ANX007 in patients with geographic atrophy (GA). The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance. A 6.2% reduction in lesion
- Alimera Completes Recruitment for Its NEW DAY Study Evaluating Iluvien for DMEhttps://modernod.com/news/alimera-completes-recruitment-for-its-landmark-new-day-study/2481633/Alimera Sciences announced that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone acetonide intravitreal implant, 0.19mg) as a baseline therapy in p
- iHealthScreen Announces FDA 510(k) Submission for iPredict Automated AI-Based AMD Toolhttps://modernod.com/news/ihealthscreen-announces-fda-510k-submission-for-ipredict-automated-ai-based-amd-tool/2481632/iHealthScreen has submitted for FDA 510(k) clearance for iPredict, making it the first company to apply for an FDA clearance for screening AMD, according to a company news release. iPredict AI Eye Screening System provides fully automated age-related macular degener
- Partnership Agreement Between Mireca and Graybug Terminatedhttps://modernod.com/news/partnership-agreement-between-mireca-and-graybug-terminated/2481631/Mireca Medicines announced that the partnership agreement between Mireca and Graybug (now CalciMedica) has been terminated due to a shift in drug development focus of CalciMedica away from ocular diseases. As part of the termination, all intellectual property rights that